Improving detection of Primary Aldosteronism using the ARR test
Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)
This study is testing a blood test to see if it can help find more people with Primary Aldosteronism, a condition that causes high blood pressure and can be treated effectively.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | The Cleveland Clinic Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Trial ID | NCT05757076 on ClinicalTrials.gov |
What this trial studies
This project aims to enhance the detection of Primary Aldosteronism (PA), a leading cause of secondary hypertension that can be treated surgically or with targeted medications. The study focuses on the relationship between hypertension, elevated aldosterone secretion, and suppressed renin levels, which are characteristic of PA. By utilizing a blood test for the Aldosterone Renin Ratio (ARR), the study seeks to identify more patients who may be suffering from this under-recognized condition. The goal is to improve case detection rates, which are currently much lower than the actual prevalence of PA.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 65 with a diagnosis of Essential Hypertension.
Not a fit: Patients currently on mineralocorticoid antagonist therapy or those already diagnosed with Primary Aldosteronism will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and effective treatments for patients with Primary Aldosteronism, potentially reducing cardiovascular risks.
How similar studies have performed: Other studies have indicated that improved detection methods for PA can significantly enhance patient outcomes, suggesting this approach has potential based on previous findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Consent to participate in the study * Participants limited to subjects in the CCF * Age between and inclusive of 18 and 65 years of age * No gender exclusion * Patients diagnosed with Essential Hypertension by ICD-10 code on at least two occasions in the previous six months, even if not on medications for hypertension * Patients on a single anti-hypertensive medication for at least six months with the diagnosis of hypertension Exclusion Criteria: * Those on a mineralocorticoid antagonist therapy (spironolactone, eplerenone) * Those with a documented diagnosis of primary aldosteronism or primary hyperaldosteronism * Those with a diagnosis of secondary hyperaldosteronism * Those with a diagnosis of heart failure, renal artery stenosis, cirrhosis, ascites, cor pulmonale. * Pregnancy status (verbal)
Where this trial is running
Cleveland, Ohio
- The Cleveland Clinic Foundation — Cleveland, Ohio, United States (Recruiting)
Study contacts
- Study coordinator: Kimberly Jenkins, MSNM
- Email: jenkink@ccf.org
- Phone: 216-445-4791
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.